<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03020719</url>
  </required_header>
  <id_info>
    <org_study_id>GROW-IP-16</org_study_id>
    <nct_id>NCT03020719</nct_id>
  </id_info>
  <brief_title>The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis</brief_title>
  <acronym>GROW</acronym>
  <official_title>A Multi Center Placebo Controlled Double Blind Randomized Study Evaluating the Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, placebo-controlled (Phase II) study will be to further
      evaluate the effects of oral glutathione on growth in children with CF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      a prospective, multi-center, randomized, placebocontrolled, double-blind, Phase II clinical
      trial. Approximately sixty pancreatic insufficient (PI) subjects with CF who are ≥ 2 and &lt; 11
      years of age, will be enrolled to receive either L-Glutathione Reduced (GSH) or placebo given
      orally (tid) for 24 weeks. Each subject will be seen for four study visits: Visit 1
      (Screening), Visit 2 (Baseline/Randomization, Day 0), Visit 3 (Week 12) and Visit 4 (Week
      24). At Visit 2, subjects will be randomized to receive either active treatment or placebo.
      Visit 1 and 2 may be combined if subject meets eligibility requirements and a fecal specimen
      is collected prior to dosing. Safety and clinical outcomes will be assessed throughout the
      study. Assessment of inflammatory and other bio-markers in blood and fecal specimens will be
      performed at Visits 2 and 4
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>investigate the effect of 24 weeks of treatment with oral glutathione on change in weight-for-age z-scores</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Z-score (or SD-score) = (observed value - median value of the reference population) / standard deviation value of reference population</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Oral Glutathione</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Glutathione oral powder at 65mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral powder at 65mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Glutathione</intervention_name>
    <description>Oral Glutathione oral powder</description>
    <arm_group_label>Oral Glutathione</arm_group_label>
    <other_name>GSH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral powder</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive powder</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥ 2 and &lt; 11 years of age at Visit 1

          2. Documentation of a CF diagnosis as evidenced by the following criteria: Sweat chloride
             ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT) AND Two
             well-characterized mutations in the cystic fibrosis transmembrane conductive regulator
             (CFTR) gene

          3. Weight-for-age between the 10th and 50th percentiles at Screening (Visit 1) (using the
             Center for Disease Control (CDC) reference equations)

          4. Current chronic use, greater than 8 weeks before Day 0, of pancreatic enzyme
             replacement therapy (PERT) for management of pancreatic insufficiency

          5. Written informed consent (and assent when applicable) obtained from subject or
             subject's legal representative and ability to comply with the requirements of the
             study

          6. Clinically stable with no significant changes in health status within 2 weeks prior to
             Day 0

        Exclusion Criteria:

          -  1. Intestinal obstruction or gastrointestinal surgery within the 6 months prior to Day
             0 2. History of diabetes, Crohn's disease, celiac disease, or bowel resection 3. Use
             of either oral or inhaled GSH or N-acetyl cysteine within the 4 months prior to
             Screening (Visit 1) 4. Known hypersensitivity to oral glutathione or lactose 5.
             Initiation of any new chronic therapy (e.g., ibuprofen, hypertonic saline,
             azithromycin, Pulmozyme, Cayston TOBI Kalydeco,Orkambi, Proton Pump Inhibitor,
             Histamine H-2 Blocker [PPI/H2-blocker], Miralax® , PERT, dietary supplementation,
             probiotics) within the 4 weeks prior to Day 0 6. Changes in the amount of proprietary
             dietary supplement formulas (e.g., Scandishakes, Boost, Pediasure, or homemade
             formula) given (oral or gastrostomy tube) within the 4 weeks prior to Day 0 7. Use of
             antibiotics (oral, IV, or inhaled) for acute symptoms within the 2 weeks prior to Day
             0 8. Use of oral steroids within the 4 weeks prior to Day 0 9. Active treatment for
             nontuberculous mycobacteria (NTM) at Day 0 10. Active treatment for allergic
             bronchopulmonary aspergillosis (ABPA) at Day 0 11. Administration of any
             investigational drug within the 30 days prior to Day 0 12. Sibling who received study
             drug as part of this study 13. Presence of a condition or abnormality that in the
             opinion of the investigator would compromise the safety of the patient or the quality
             of the data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah J Schwarzenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Molly Bozic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine Riley Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liebe Antoine, CCRA</last_name>
    <phone>206-884-7510</phone>
    <email>liebe.antoine@seattlechildrens.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Childrens Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Infante</last_name>
      <phone>720-777-2941</phone>
      <email>Rebecca.Infante@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Scott Sagel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Childrens Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masai McIntosh</last_name>
      <phone>860-837-7568</phone>
      <email>MMcIntosh@connecticutchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Craig Lapin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Childrens Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth DeLuca</last_name>
      <phone>904-697-3804</phone>
      <email>Elizabeth.DeLuca@nemours.org</email>
    </contact>
    <investigator>
      <last_name>David Schaeffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Davis</last_name>
      <phone>850-473-4553</phone>
      <email>Rebecca.Davis@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Okan Elidemir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linton Cuff</last_name>
      <phone>404-712-2493</phone>
      <email>linton.cuff@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Alvin Freeman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Children's Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Klipsch</last_name>
      <phone>317-944-9605</phone>
      <email>aeye@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Molly Bozic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Driscoll</last_name>
      <phone>313-745-4737</phone>
      <email>ddriscol@med.wayne.edu</email>
    </contact>
    <investigator>
      <last_name>James Cahill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Women and Childrens Center</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Gile</last_name>
      <phone>616-391-6148</phone>
      <email>Cynthia.Gile@spectrumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Susan Millard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooke Noren, RN</last_name>
      <phone>612-625-7995</phone>
      <email>boer0039@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah J Schwarzenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Childrens Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Williams</last_name>
      <phone>816-760-5591</phone>
      <email>knwilliams@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Hugo Escobar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women and Childrens Hospital of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine Caci</last_name>
      <phone>716-878-7524</phone>
      <email>ncaci@upa.chob.edu</email>
    </contact>
    <investigator>
      <last_name>Danielle Goetz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of New York/Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Lusman, MD</last_name>
      <phone>212-305-7815</phone>
      <email>ses2005@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Lusman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Simeon</last_name>
      <phone>503-494-6180</phone>
      <email>simeon@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Amy Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniyal Kamal</last_name>
      <phone>214-456-5489</phone>
      <phone_ext>11532</phone_ext>
      <email>Daniyal.Kamal@childrens.com</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Stephenson</last_name>
      <phone>214-456-4794</phone>
      <email>Elizabeth.Stephenson@childrens.com</email>
    </contact_backup>
    <investigator>
      <last_name>Meghana Sathe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Banks</last_name>
      <phone>832-824-7608</phone>
      <email>Christina.Banks@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Jensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Vermont Inc.</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Sweet</last_name>
      <phone>802-847-7958</phone>
      <email>Julie.Sweet@uvmhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Joan Lippman</last_name>
      <phone>802-847-6982</phone>
      <email>joan.lippman@uvmhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jillian Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Moss</last_name>
      <phone>434-243-2876</phone>
      <email>pcm2v@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Froh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Milwaukee</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Hastings</last_name>
      <phone>414-226-6986</phone>
      <email>phastings@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Noe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2017</study_first_submitted>
  <study_first_submitted_qc>January 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Growth Parameters</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

